RELATED STORY: Lloyd Trotman: Transforming Views of Prostate Cancer
Lloyd Trotman earned his M.S. in biochemistry and his Ph.D. in cell biology from the University of Zurich. He was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, and joined Cold Spring Harbor in 2007. He has received the Pershing Square Sohn Prize for Young Investigators in Cancer Research from Pershing Square Sohn Cancer Research Alliance and the American Society for Cell Biology’s Merton R. Bernfield Memorial Award. He also has been named an American Cancer Society Scholar and a V Foundation Scholar. His research has been supported by a Department of Defense (DOD) Prostate Cancer Idea Award, a DOD Prostate Cancer Research Program New Investigator Award, a V. Kann Rasmussen Foundation Award and a Starr Cancer Consortium Grant Award.
With more than 200,000 U.S. cases per year, prostate cancer is the most commonly diagnosed malignancy in men and the second most common cause of male cancer deaths. Trotman’s lab aims to understand lethal prostate cancer and to speed up the search for a cure. While progress in clinical research is naturally limited by the established standards of care, therapy using animal models is not. Model therapy, in contrast, is limited by the qualities of the model system. Based on their analysis of human cancer genomes, Trotman and his team have generated a first-in-kind mouse model for tracking of endogenous metastatic prostate cancer, termed RapidCaP. This system allows for live visualization of metastasis and therapy failure and for molecular/genetic dissection of these processes.